5α-Reductase inhibitors

Journal of Andrology

Volumn 18, Issue 6, 1997, Pages 582-587

  Rittmaster, Roger S ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Victoria Building ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN; ANDROSTANOLONE; ENZYME INHIBITOR; TESTOSTERONE;

ACNE; DRUG ACTIVITY; DRUG EFFECT; DRUG INDICATION; ENZYME INHIBITION; GYNECOMASTIA; HIRSUTISM; HUMAN; IMPOTENCE; MALE TYPE ALOPECIA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SEXUAL DYSFUNCTION; SHORT SURVEY; DRUG ANTAGONISM; ENZYMOLOGY; MALE; METABOLISM; PATHOLOGY; PROSTATE; REVIEW;

DIHYDROTESTOSTERONE; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0031283203     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (61)

1. Andersen JT, Ekman P, Wolf H, Beisland HO, Johanson JE, Kontturi M, Lehtonen T, Tveter K, Scandinavian BPH Study Group. Can finasteride reverse the progress of benign prostatic hyperplasia? A 2-year placebo-controlled study. Urology 1995;46:631-637.
2. Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997;49:839-845.
3. Andriole G, Lieber M, Smith J, Soloway M, Schroeder F, Ramsey E, Perreault J, Trachtenberg J, Fradet Y, Block N, Middleton R, Ng J, Ferguson D, Gormley GJ. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995;45:491-497.
4. Aumuller G, Eicheler W, Renneberg H, Aldermann K, Vilja P, Forssmann W-G. Immunocytochemical evidence for differential subcellular localization of 5α-reductase isoenzymes in human tissue. Acta Anat 1996;156:241-252.
5. Bonkhoof H, Stein U, Aumuller G, Remberger K. Differential expression of 5α-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 1996;29:261-267.
6. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48:398-405.
7. Castello M, Tosi F, Perrone F, Negri C, Muggeo M, Moghetti P. Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil Steril 1996;66:734-740.
8. Ciotta L, Cianci A, Calogero AE, Palumbo MA, Marietta E, Sciuto A, Palumbo G. Clinical and endocrine effects of finasteride, a 5α-reductase inhibitor, in women with idiopathic hirsutism. Fertil Steril 1995; 64:299-306.
9. Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL, Nguyen HH, Moore EC, Tanaka WK. The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994;79:703-706.
10. Delos S, Iehle C, Martin PM, Raynaud JP. Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 1994;48:347-352.
11. Deslypere J-P, Young M, Wilson JD, McPhaul MJ. Testosterone and 5α-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 1992;88:15-22.
12. Eicheler W, Dreher M, Hoffmann R, Happle R, Aumuller G. Immunohistochemical evidence for differential distribution of 5α-reductase isoenzymes in human skin. Br J Dermatol 1995;133:371-376.
13. Eicheler W, Tuohimaa P, Vilja P, Adermann K, Forssmann W-G, Aumuller G. Immunocytochemical localization of human 5α-reductase 2 with polyclonal antibodies in androgen target and non-target human tissues. J Histochem Cytochem 1994;42:667-675.
14. Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA Jr., Brawley OW, Ford LG. Design of the prostate cancer prevention trial (PCPT). Control Clin Trials 1995;16:150-163.
15. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993;22:291-299.
16. Fleshner NE, Trachtenberg J. Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results. Eur Urol (Suppl 2) 1993;24:106-112.
17. Fratianni CM, Imperato-McGinley J. The syndrome of 5α-reductase deficiency. Endocrinologist 1994;4:302-314.
18. Geller J. Effect of finasteride, a 5α-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 1990;71:1552-1555.
19. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GE, Geller J, Bracken BR, Tenover JS, Vaughan D, Pappas F, Taylor A, Binkowitz B, Ng J. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-1191.
20. Gormley GJ, Stoner E, Rittmaster RS, Gregg H, Thompson DE, Lasseter KC, Vlasses PH, Stein EA. Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990;70:1136-1141.
21. Green L, Wysowski DK, Fourcroy JL. Gynecomastia and breast cancer during finasteride therapy. [Letter to the editor.] N Engl J Med 1996; 335:823.
22. Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990;126:1165-1172.
23. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996; 155:3-9.
24. Hirsch KS, Jones CD, Audia JE, Andersson S, McQuaid L, Stamm NB, Neubauer BL, Pennington P, Toomey RE, Russell DW. LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1. Proc Natl Acad Sci USA 1993;90:5277-5281.
25. Imperato-McGinley J, Gautier T, Cai L-Q, Yee B, Epstein J, Pochi P. The androgen control of sebum production. Comparison of subjects with selective dihydrotestosterone deficiency, subjects with complete androgen insensitivity and normal controls. J Clin Endocrinol Metab 1993;76:524-528.
26. Imperato-McGinley J, Gautier T, Zirinsky K, Hom T, Palomo O, Stein E, Vaughan ED, Markisz JA, Ramirez de Arellano E, Kazam E. Prostate visualization studies in males homozygous and heterozygous for 5α-reductase deficiency. J Clin Endocrinol Metab 1992;75:1022-1026.
27. Itami S, Kurata S, Sonoda T, Takayasu. Characterization of 5α-reductase in cultured human dermal papilla cells from beard and occipital scalp hair. J Invest Dermatol 1991;96:57-60.
28. Jenkins EP, Hsieh C-L, Milatovich A, Normington K, Berman DM, Francke U, Russell DW. Characterization and chromosomal mapping of a human steroid 5α-reductase gene and pseudogene and mapping of the mouse homologue. Genomics 1991;11:1102-1112.
29. Kaefer M, Audia JE, Bruchovsky N, Goode RL, Hsiao KC, Leibovitch IY, Krushinski JH, Lee C, Steidle CP, Sutkowski DM, Neubauer BL. Characterization of type 1 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cells. J Steroid Biochem Mol Biol 1996;58: 195-205.
30. Kaufman M, Pinsky L. The dissociation of testosterone- and 5α-dihydrotestosterone-receptor complexes formed within cultured human genital skin fibroblasts. J Steroid Biochem 1983;18:121-125.
31. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533-539.
32. Luu-The V, Sugimoto Y, Puy L, Labrie Y, Lopez Solache I, Singh M, Labrie F. Characterization, expression, and immunohistochemical localization of 5α-reductase in human skin. J Invest Dermatol 1994; 102:221-226.
33. Mahendroo MS, Cala KM, Russell DW. 5α-reduced androgens play a key role in murine parturition. Mol Endocrinol 1996;10:380-392.
34. Matzkin H, Chen J, Weisman Y, Goldray D, Pappas F, Jaccard N, Braf Z. Prolonged treatment with finasteride (a 5α-reductase inhibitor) does not affect bone density and metabolism. Clin Endocrinol (Oxf) 1992; 37:432-436.
35. McConnell JD, Wilson JD, George FW, Geller G, Pappas F, Stoner E. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505-508.
36. Moghetti P, Castello R, Magnani CM, Tosi F, Negri C, Armanini D, Bellotti G, Muggeo M. Clinical and hormonal effects of the 5α-reductase inhibitor finasteride in idiopathic hirsutism. J Clin Endocrinol Metab 1994;79:1115-1121.
37. Montironi R, Valli M, Fabris G. Treatment of benign prostatic hyperplasia with 5-α-reductase inhibitor: morphological changes in patients who fail to respond. J Clin Pathol 1996;49:324-328.
38. Neubauer BL, Gray HM, Hanke CW, Hirsch KS, Hsiao KC, Jones CD, Kumar MV, Lawhorn DE, Lindzey J, McQuaid D, Tindall DJ, Toomey RE, Yao RC, Audia JE. LY191704 inhibits type I steroid 5α-reductase in human scalp. J Clin Endocrinol Metab 1996;81:2055-2060.
39. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault J-P, Afridi SK, Elhilali MM, Group PS. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc J 1996;155: 1251-1259.
40. Ornstein DK, Rao GS, Johnson B, Charlton ET, Andriole GL. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 1996;48:901-905.
41. Presti JC Jr, Fair WR, Andriole G, Sogani PC, Seidmon EJ, Ferguson D, Ng J, Gormley GJ. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 1992;148:1201-1204.
42. Price H, McNeal JE, Stamey TA. Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum Pathol 1990;21:578-585.
43. Rittmaster RS. Finasteride. N Engl J Med 1994;330:120-125.
44. Rittmaster RS, Manning AP, Wright AS, Thomas LN, Whitefield S, Norman RW, Lazier CB, Rowden G. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology 1995;136:741-748.
45. Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996;81:814-819.
46. Schroeder FH. 5α-reductase inhibitors and prostatic disease. Clin Endocrinol (Oxf) 1994;41:139-147.
47. Schwartz JI, Van Hecken A, de Schepper PJ, de Lepeleire I, Lasseter KC, Cooper Shamblen E, Winchell GA, Constanzer ML, Chavez CM, Wang DZ, Ebel DL, Justice SJ, Gertz BJ. Effect of MK-386, a novel inhibitor of type 1 5α-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men. J Clin Endocrinol Metab 1996;81:2942-2947.
48. Shimodaira K, Fujikawa H, Okura F, Shimizu Y, Saito H, Yanaihara T. Osteoblast cells (MG-63 and HOS) have aromatase and 5α-reductase activities. Biochem Mol Biol Int 1996;39:109-116.
49. Silver RI, Wiley EL, Davis DL, Thigpen AE, Russell DW, McConnell JD. Expression and regulation of steroid 5α-reductase 2 in prostate disease. J Urol 1994a;152:433-437.
50. Silver RI, Wiley EL, Thigpen AE, Guileyardo JM, McConnell JD, Russell DW. Cell type specific expression of steroid 5α-reductase 2. J Urol 1994b;152:438-442.
51. Smith CM, Ballard SA, Worman N, Buettner R, Masaters JRW. 5α-reductse expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J Clin Endocrinol Metab 1996;81:1361-1366.
52. Stoner E. 5α-reductase inhibitors/finasteride. Prostate (Suppl) 1996;6:82-87.
53. Stoner E, Group TFS. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994;43:284-294.
54. Thigpen AE, Davis DL, Milatovich A, Mendonca B, Imperato-McGinley J, Griffin JE, Francke U, Wilson JD, Russell DW. Molecular genetics of steroid 5α-reductase 2 deficiency. J Clin Invest 1992;90:799-809.
55. Tolino A, Petrone A, Sarnacchiaro F, Cirillo D, Ronsini S, Lombardi G, Nappi C. Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril 1996;66:61-65.
56. Tollin SR, Rosen HN, Zurowski K, Saltzman B, Zeind AJ, Berg S, Greenspan SL. Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia - a clinical research center. J Clin Endocrinol Metab 1996;81:1031-1034.
57. Wilbert DM, Griffin JE, Wilson JD. Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab 1983; 56:113-120.
58. Wilson JD, Griffin JE, Russell DW. Steroid 5 alpha-reductase 2 deficiency. Endocr Rev 1993;14:577-593.
59. Wilton L, Pearce G, Edet E, Freemantle S, Stephens MDB, Mann RD. The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14 772 patients. Br J Urol 1996;78:379-384.
60. Wong IL, Morris RS, Chang L, Spahn M-A, Stanczyk FZ, Lobo RA. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsutism. J Clin Endocrinol Metab 1995;80:233-238.
61. Wright AS, Thomas LN, Douglas RC, Lazier CB, Rittmaster RS. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest 1996; 98:2558-2563.